RxDoctor Payments Data

Ye Su, DO

Neurology · Middletown, CTNPI 1003376237

Payments from drug & device makers

$1,731in general payments, 2019–2025

Across 88 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$180
  • Neurelis, Inc.$67
  • MDD US Operations, LLC$65
  • SK Life Science, Inc.$49
  • Baxter Healthcare$47
  • plus $215 from 8 others

What the payments were for

  • Food & beverage$1,731100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,731 in reported general payments places this provider in the 50th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$14,519
Medicare patients
57
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant40$47,944
QuliptaAtogepant36$43,263
Nurtec OdtRimegepant Sulfate30$41,287
Emgality PenGalcanezumab-Gnlm49$38,260
Aimovig AutoinjectorErenumab-Aooe20$16,104
Ajovy AutoinjectorFremanezumab-Vfrm16$12,983
Sumatriptan13$1,691
Sumatriptan Succinate25$902
Naratriptan Hcl21$668
RizatriptanRizatriptan Benzoate23$408
Gabapentin15$227
Prochlorperazine Maleate11$90
Donepezil Hcl13$86
Metoclopramide Hcl47$84
Topiramate13$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,109$91,20776 claims
PfizerNurtec Odt$180$41,28730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 280 neurology providers in Connecticut.

Other neurology in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →